Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 46)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 4 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
2 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
3 |
|
Ascorbic acid |
Approved, Nutraceutical |
Phase 4 |
|
50-81-7 |
54676860 54670067 5785 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
[<sup>14</sup>C]-ascorbic acid
3-keto-L-Gulofuranolactone
3-oxo-L-Gulofuranolactone
AA
Acid, ascorbic
Acid, L-ascorbic
Acide ascorbique
Acido ascorbico
ácido ascórbico
Acidum ascorbicum
Acidum ascorbinicum
Adenex
Allercorb
Antiscorbic vitamin
Antiscorbutic vitamin
arco-Cee
Ascoltin
ASCOR
Ascorb
Ascor-b.i.d.
Ascorbajen
Ascorbate
Ascorbate radical
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ASCORBIC ACID
Ascorbic acid radical
Ascorbic acid, monosodium salt
Ascorbicab
Ascorbicap
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorin
Ascorteal
Ascorvit
Cantan
Cantaxin
Catavin C
Ce lent
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
Cevatine
Cevex
Cevi-bid
Cevimin
Ce-vi-sol
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
|
Ciamin
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
Concemin
C-Quin
C-Span
C-Vimin
Davitamon C
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
HiCee
Hybrin
ido-C
Juvamine
Kangbingfeng
Kyselina askorbova
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-Ascorbate
L-Ascorbic acid
Lemascorb
Liqui-cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-threo-Ascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Monodehydroascorbate radical
Monodehydroascorbic acid radical
Natrascorb
Natrascorb injectable
Planavit C
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Semidehydroascorbic acid
Sodascorbate
Sodium ascorbate
Suncoat VC 40
Testascorbic
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamina C
Vitamisin
Vitascorbol
Xitix
|
|
4 |
|
Antioxidants |
|
Phase 4 |
|
|
|
5 |
|
Protective Agents |
|
Phase 4 |
|
|
|
6 |
|
Folate |
|
Phase 4 |
|
|
|
7 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
8 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
9 |
|
Hematinics |
|
Phase 4 |
|
|
|
10 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
11 |
|
Polymethyl Methacrylate |
|
Phase 4 |
|
|
|
12 |
|
Vitamins |
|
Phase 4 |
|
|
|
13 |
|
Trace Elements |
|
Phase 4 |
|
|
|
14 |
|
Micronutrients |
|
Phase 4 |
|
|
|
15 |
|
Dialysis Solutions |
|
Phase 3 |
|
|
|
16 |
|
Basiliximab |
Approved, Investigational |
Phase 1, Phase 2 |
|
179045-86-4 |
|
Synonyms:
BASILIXIMAB
CHI621
CHI-621
CHI-621|L04AC02|SDZ-CHI-621|Simulect®
|
CHIMERIC MOUSE-HUMAN ANTICD25
IG GAMMA-1 CHAIN C REGION
SDZ-CHI-621
SIMULECT
|
|
17 |
|
Bortezomib |
Approved, Investigational |
Phase 1, Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
18 |
|
Cysteine |
Approved, Nutraceutical |
Phase 2 |
|
52-90-4 |
594 5862 |
Synonyms:
(+)-2-AMINO-3-MERCAPTOPROPIONIC ACID
(2R)-2-AMINO-3-MERCAPTOPROPANOATE
(2R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(2R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(2R)-2-AMINO-3-SULFANYLPROPANOATE
(2R)-2-AMINO-3-SULFANYLPROPANOIC ACID
(2R)-2-AMINO-3-SULFANYL-PROPANOIC ACID
(2R)-2-Amino-3-sulphanylpropanoate
(2R)-2-Amino-3-sulphanylpropanoic acid
(R)-(+)-CYSTEINE
(R)-2-AMINO-3-MERCAPTOPROPANOATE
(R)-2-AMINO-3-MERCAPTO-PROPANOATE
(R)-2-AMINO-3-MERCAPTOPROPANOIC ACID
(R)-2-AMINO-3-MERCAPTO-PROPANOIC ACID
(R)-CYSTEINE
2-Amino-3-mercaptopropanoate
2-Amino-3-mercaptopropanoic acid
2-Amino-3-mercaptopropionate
2-Amino-3-mercaptopropionic acid
2-Amino-3-sulfanylpropanoate
2-Amino-3-sulfanylpropanoic acid
2-Amino-3-sulphanylpropanoate
2-Amino-3-sulphanylpropanoic acid
3-MERCAPTO-L-ALANINE
ACETYLCYSTEINE
ALPHA-AMINO-BETA-THIOLPROPIONIC ACID
BETA-MERCAPTOALANINE
B-MERCAPTOALANINE
C
CARBOCYSTEINE
Cisteina
|
CISTEINUM
Cys
Cystein
Cysteine
CYSTEINE HCL
Cysteine hydrochloride
CYSTEINUM
E 920
E920
E-920
E921
Ecolan
FREE CYSTEINE
Half cystine
Half-cystine
Hcys
L Cysteine
L-(+)-CYSTEINE
L-2-AMINO-3-MERCAPTOPROPANOATE
L-2-AMINO-3-MERCAPTOPROPANOIC ACID
L-2-Amino-3-mercaptopropionate
L-2-AMINO-3-MERCAPTOPROPIONIC ACID
L-CYS
L-CYSTEIN
L-Cysteine
L-ZYSTEIN
POLYCYSTEINE
THIOSERINE
Zinc cysteinate
Zystein
|
|
19 |
|
Immunosuppressive Agents |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Immunologic Factors |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Immunoglobulins |
|
Phase 1, Phase 2 |
|
|
|
22 |
|
Antibodies |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
24 |
|
Gabapentin |
Approved, Investigational |
|
|
60142-96-3 |
3446 |
Synonyms:
1-(Aminomethyl)cyclohexaneacetate
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
Aclonium
Apo gabapentin
Apo-gabapentin
ApoGabapentin
CI 945
CI 945|Go 3450|GOE 2450|GOE 3450|Neurontin®
CI-945
Convalis
DM-1796
GABAPENTIN
GABAPENTIN GR
Gabapentin hexal
Gabapentin ratiopharm
Gabapentin stada
Gabapentina
Gabapentine
|
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentin-ratiopharm
Gabapentinum
Gabapentinum [INN-Latin]
Gabapetin
GO 3450
GOE 2450
GOE 3450
GOE-3450
Gralise
Neurontin
Novo gabapentin
Novo-gabapentin
NovoGabapentin
Novo-gabapentine
PMS-Gabapentin
|
|
25 |
|
Pancrelipase |
Approved, Investigational |
|
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
26 |
|
Ritonavir |
Approved, Investigational |
Early Phase 1 |
|
155213-67-5 |
392622 |
Synonyms:
538, ABT
A-84538
A-84538|ABBOTT-84538|ABT 538|ABT-538|Norvir®|RTV
Abbott 84538
ABBOTT-84538
ABT 538
ABT-538
|
N-[(1S,3S,4S)-1-BENZYL-3-HYDROXY-5-PHENYL-4-{[(1,3-THIAZOL-5-YLMETHOXY)CARBONYL]AMINO}PENTYL]-N~2~-(METHYL{[2-(1-METHYLETHYL)-1,3-THIAZOL-4-YL]METHYL}CARBAMOYL)-L-VALINAMIDE
Norvir
Norvir Sec
NSC-693184
Ritonavir
RITONAVIR RELATED COMPOUNDS MIXTURE
Ritonavirum
|
|
27 |
|
Carbamide peroxide |
Approved |
|
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
28 |
|
Gastric inhibitory polypeptide |
Investigational |
|
|
100040-31-1 |
|
Synonyms:
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
|
|
|
29 |
|
Indole |
Experimental |
|
|
120-72-9 |
798 |
Synonyms:
1-Azaindene
1-Benzazole
2,3-Benzopyrrole
Benzo[b]pyrrole
|
|
|
30 |
|
Anti-Anxiety Agents |
|
|
|
|
|
31 |
|
Neurotransmitter Agents |
|
|
|
|
|
32 |
|
Psychotropic Drugs |
|
|
|
|
|
33 |
|
Excitatory Amino Acid Antagonists |
|
|
|
|
|
34 |
|
Anticonvulsants |
|
|
|
|
|
35 |
|
Analgesics |
|
|
|
|
|
36 |
|
Anti-Infective Agents |
|
|
|
|
|
37 |
|
Hormones |
|
|
|
|
|
38 |
|
Glucagon-Like Peptide 1 |
|
|
|
|
|
39 |
|
Incretins |
|
|
|
|
|
40 |
|
Pancreatin |
|
|
|
|
|
41 |
|
Gastrointestinal Agents |
|
|
|
|
|
42 |
|
Anti-Bacterial Agents |
|
Early Phase 1 |
|
|
|
43 |
|
HIV Protease Inhibitors |
|
Early Phase 1 |
|
|
|
44 |
|
Antibiotics, Antitubercular |
|
Early Phase 1 |
|
|
|
45 |
|
protease inhibitors |
|
Early Phase 1 |
|
|
|
Synonyms:
|
46 |
|
D-Alanine |
Experimental, Nutraceutical |
|
|
302-72-7, 338-69-2, 56-41-7 |
101757026 602 71080 5950 |
Synonyms:
(2R)-2-Aminopropanoate
(2R)-2-Aminopropanoic acid
(2R)-2-Aminopropionic acid
(2S)-2-Aminopropanoate
(2S)-2-AMINOPROPANOIC ACID
(a-D-Mannosyl)7-b-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
(R)-2-Aminopropanoate
(R)-2-Aminopropanoic acid
(R)-2-Aminopropionic acid
(R)-Alanine
(S)-(+)-Alanine
(S)-2-Aminopropanoate
(S)-2-Amino-propanoate
(S)-2-Amino-propanoic acid
(S)-2-AMINOPROPANOIC ACID
(S)-ALANINE
(Α-D-mannosyl)7-β-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
[<sup>14</sup>C]-alanine
[<sup>3</sup>H]-alanine
2-Aminopropanoate
2-Aminopropanoic acid
2-Aminopropionate
2-Aminopropionic acid
2-Ammoniopropanoate
2-Ammoniopropanoic acid
A
a-Alanine
a-Aminopropionate
a-Aminopropionic acid
Abufène
ALA
Alanin
Alanina
Alanine
Alanine doms-adrian brand
Alanine, L isomer
Alanine, L-isomer
Alaninum
alpha-Alanine
alpha-Aminopropanoate
alpha-Aminopropanoic acid
alpha-Aminopropionate
|
alpha-Aminopropionic acid
D(-)-a -Alanine
D-(-)-Alanine
D(-)-alpha-Alanine
D(-)-Α-alanine
D-2-Aminopropionate
D-2-Aminopropionic acid
D-a-Alanine
D-a-Aminopropionate
D-a-Aminopropionic acid
DAL
D-Ala
D-Alanin
D-ALANINE
D-alpha-Alanine
D-alpha-Aminopropionate
D-alpha-Aminopropionic acid
Doms adrian brand OF alanine
Doms-adrian brand OF alanine
D-Α-alanine
D-Α-aminopropionate
D-Α-aminopropionic acid
E639
Ellagate arabinoside
L Alanine
L-(+)-Alanine
L-2-Aminopropanoate
L-2-Aminopropanoic acid
L-2-Aminopropionate
L-2-AMINOPROPIONIC ACID
L-a-Alanine
L-a-Aminopropionate
L-a-Aminopropionic acid
L-ALA
L-Alanin
L-Alanine
L-ALPHA-ALANINE
L-alpha-Aminopropionate
L-alpha-Aminopropionic acid
L-Isomer alanine
L-Α-ALANINE
NSC-206315
|
|
Interventional clinical trials:
(show all 30)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis |
Unknown status |
NCT01076426 |
Phase 4 |
Pro-biotics |
2 |
Efficacy and Safety of a Very Low Protein Diet in Postponing Dialysis in Elderly: a Prospective Randomized Multicenter Controlled Study |
Completed |
NCT00388648 |
Phase 4 |
mixture of amino and keto acids |
3 |
Randomized Clinical Trial of Folate Therapy/Placebo for Reduction of Homocysteine Serum Levels in Uremic Patients and Influence on Cardiovascular Mortality |
Completed |
NCT00317005 |
Phase 4 |
folate treatment |
4 |
ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease. |
Completed |
NCT00649298 |
Phase 4 |
|
5 |
Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney |
Completed |
NCT00442819 |
Phase 4 |
|
6 |
Effect of Oral Vitamin C on The Inflammatory Biomarkers in Hemodialysis |
Completed |
NCT01356433 |
Phase 4 |
oral vitamin C |
7 |
The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients |
Completed |
NCT02747979 |
Phase 2, Phase 3 |
|
8 |
Effects of Convective Therapies in Dialysis Patients |
Completed |
NCT01583309 |
Phase 3 |
|
9 |
Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Randomized Controlled Trial |
Unknown status |
NCT02492490 |
Phase 1, Phase 2 |
Basiliximab |
10 |
A Prospective, Open-Label, Pilot Study of Clonal Deletion on Living-Relative Donor Kidney Transplantation |
Unknown status |
NCT01408797 |
Phase 1, Phase 2 |
MMF, Bortezomib |
11 |
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY TO EVALUATE THE RENAL AND BIOHUMORAL EFFECTS OF L-CYSTEINE COMPARED TO PLACEBO IN STABLE PERITONEAL DIALYSIS PATIENTS WITH RESIDUAL DIURESIS |
Completed |
NCT02050139 |
Phase 2 |
|
12 |
Clinical and Biochemical Effects of Multipass Hemodialysis |
Completed |
NCT01267760 |
Phase 2 |
|
13 |
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma |
Withdrawn |
NCT00172367 |
Phase 2 |
Lycopene |
14 |
Removal of Protein Bound Uremic Toxins in Chronic Hemodialysis Patients by Modified Plasma Separation and Adsorption Combined With Hemodialysis |
Unknown status |
NCT00375635 |
|
|
15 |
Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW? |
Unknown status |
NCT02606955 |
|
|
16 |
REST/Collaborative Study Initiative With the Aim of Providing More Objective Information on Volume Status and Guiding Physicians in the Quest for DW |
Unknown status |
NCT02446535 |
|
|
17 |
Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan |
Unknown status |
NCT01766895 |
|
|
18 |
Randomized Controlled Trial to Compare Therapeutic Effect of Digital Subtraction Angiography(DSA),Ultrasound Guided Balloon Dilatation and Surgical Reconstruction in Arteria-venous Fistula(AVF) Stenosis in Maintenance Hemodialysis Patients |
Unknown status |
NCT02266238 |
|
|
19 |
Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study |
Unknown status |
NCT00577967 |
|
Gabapentin |
20 |
Effect of Fructose and Glucose and TAS1R2 in Glucose, Triglycerides, Uremia, Oxidative Stress, Feelings Related to Food Intake of Individuals With Type 1 Diabetes |
Completed |
NCT01713023 |
|
|
21 |
In Vitro Evaluation of Antibacterial Activity of Urea Solution Against Ocular Bacterial Isolates |
Completed |
NCT04020406 |
|
|
22 |
Elimination and Biodegradation of the Incretin Hormones GLP-1 and GIP in Patients With End-stage Renal Disease |
Completed |
NCT01391884 |
|
|
23 |
Reduction Ratio and Clearance of Middle Molecules During a Single Hemodialysis Session With Medium Cut-Off (MCO) Filter Compared to Hemodiafiltration (HDF) With Standard High-flux Filter |
Completed |
NCT03437538 |
|
|
24 |
Detection and Identification of Preeclampsia Via Volatile Biomarkers |
Completed |
NCT01291342 |
|
|
25 |
Dysregulated Urea-synthesis at Terminal Uremia |
Recruiting |
NCT05076318 |
|
|
26 |
Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus |
Recruiting |
NCT05497232 |
|
|
27 |
The Effect of Paxlovid in the Treatment of COVID-19 Patients With Uremia |
Not yet recruiting |
NCT05386433 |
Early Phase 1 |
Paxlovid;standard-of-care |
28 |
Assessment of the Production of Uremic Toxins by the Gut Microbiota of Patients With Chronic Kidney Disease: in Vitro Test |
Not yet recruiting |
NCT04768309 |
|
|
29 |
Early vs Late CRRT, a Propensity Matched Multicenter Cohort Study |
Not yet recruiting |
NCT03629977 |
|
|
30 |
12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter. |
Withdrawn |
NCT03416192 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Activated Charcoal
Charcoal
|
CHARCOAL,ACTIVATED PWDR
|
Cochrane evidence based reviews: uremia
|